<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01098591</url>
  </required_header>
  <id_info>
    <org_study_id>MUW - Meta</org_study_id>
    <nct_id>NCT01098591</nct_id>
  </id_info>
  <brief_title>Meta-Analysis of Cell-based CaRdiac stUdiEs: ACCRUE</brief_title>
  <acronym>ACCRUE</acronym>
  <official_title>Meta-Analysis of Cell-based CaRdiac stUdiEs: ACCRUE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Silesia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VZW Cardiovascular Research Center Aalst</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Military Medical Academy, Belgrade, Serbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novosibirsk Scientific Research Institute for Circulatory Pathology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asklepios Kliniken Hamburg GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Debrecen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Targu Mures, Romania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Clinic for Cardiology, Skopje, Republic of Macedonia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>State Health Center, Hungary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oulu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Minneapolis Heart Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinik Hirslanden, Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Numerous human cardiac stem cell studies have been published, including relatively small&#xD;
      number of patients. Meta-analysis of randomized trials have reported safety and a 3-6%&#xD;
      increase in global left ventricular performance after intracoronary stem cell therapy in&#xD;
      patients with acute myocardial infarction. Since most of the studies used different type of&#xD;
      stem cells, delivery modes, and patient population, the results are heterogenous, therefore&#xD;
      the comparison of the results is biased regarding generalizable conclusions about the effect&#xD;
      of treatment. The present comparative meta-analysis is based on individual patient data, and&#xD;
      gathers and pools the raw data, and analyzes the clinical outcome, safety and efficacy of the&#xD;
      cardiac stem cell therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Background: Many clinical trials and meta-analyses presented moderate but significant&#xD;
           improvement of the left ventricular ejection fraction (LVEF) after intracoronary&#xD;
           autologous bone-marrow (BM) or peripheral blood origin stem cells transfer. However, it&#xD;
           remains controversial, whether this beneficial effects is comparable with the&#xD;
           intramyocardial delivery of the stem cells, or could be maintained during moderate and&#xD;
           long term follow-up. The BOOST trial suggested that cardiac stem cell therapy did not&#xD;
           improve LVEF at 5-year follow-up. By contrast, BALANCE study showed a long sustained&#xD;
           benefit of BM-stem cells treatment. Due to these divergent outcomes of the presented&#xD;
           trials, the aim of the present meta-analysis is to compare the safety and effectiveness&#xD;
           of the cardiac stem cell therapy in different patient population, delivery mode and cell&#xD;
           type, to find out, which patients with which therapy mode can have the greatest benefit&#xD;
           from cardiac stem cell therapy.&#xD;
&#xD;
        -  Study design: individual patient data meta-analysis&#xD;
&#xD;
        -  Data sources: European Centre performing human cardiac stem cell therapy have been&#xD;
           contacted calling for participation.&#xD;
&#xD;
        -  Methods: Individual data gathering and entering into the database for a pooled analysis.&#xD;
           The meta-analysis will be done in line with recommendation from the Cochrane&#xD;
           Collaboration and the Quality of Reporting of Meta-analyses guidelines with Review&#xD;
           Manager 5.0. Fixed-effect model will be used.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2007</start_date>
  <completion_date type="Actual">December 2020</completion_date>
  <primary_completion_date type="Actual">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from occurrence of major adverse cardiac and cerebrovascular events (MACCE), including all-cause death, re-infarction, revascularization and stroke</measure>
    <time_frame>12 months</time_frame>
    <description>MACCE is defined as all-cause death, re-infarction, revascularization and stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hard clinical end point</measure>
    <time_frame>12 months</time_frame>
    <description>all-cause death, re-infarction and stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in end-diastolic volume</measure>
    <time_frame>12 months</time_frame>
    <description>End-diastolic volume is an index of ventricular remodeling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in end-systolic volume</measure>
    <time_frame>12 months</time_frame>
    <description>Index of ventricular systolic performance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ejection fraction</measure>
    <time_frame>12 months</time_frame>
    <description>Improvement of systolic cardiac function after cell therapy</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">3500</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>Myocardial infarction</arm_group_label>
    <description>Patients with post-myocardial infarction receiving cell therapy either intracoronarily or intramyocardial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ischemic cardiomyopathy</arm_group_label>
    <description>Patients with ischemic cardiomyopathy treated with cell therapy either intracoronarily or intramyocardial</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cell therapy</intervention_name>
    <arm_group_label>Ischemic cardiomyopathy</arm_group_label>
    <arm_group_label>Myocardial infarction</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with cell-based cardiac therapy at one of the participating centers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient included in one of the registered cell-based cardiac therapy of the&#xD;
             participating center&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariann Gyongyosi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://circres.ahajournals.org/content/early/2015/02/19/CIRCRESAHA.116.304346.long</url>
    <description>Publication</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 30, 2010</study_first_submitted>
  <study_first_submitted_qc>April 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2010</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Mariann Gyongyosi</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>meta-analysis</keyword>
  <keyword>stem cell</keyword>
  <keyword>cardiac</keyword>
  <keyword>remodeling</keyword>
  <keyword>ACCRUE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

